CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Lifestyle Modifications for Preventing and Treating Heart Failure The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure Dapagliflozin for treating chronic heart failure with reduced ejection fraction Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection Fraction 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study
|<<... 9 10 11 12 13 14 15 16 >>|

Clinical TrialDecember 8, 2020 Vol 142, Issue 23

JOURNAL：Circulation. Article Link

Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial

F Cosentino , CP Cannon , DZI Cherney et al. Keywords: ertugliflozin;T2DM; ASCVD, HF

Full Text PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top